Atlas

While the automotive classified space gets little love from momentum traders, Cars.com presents an intriguing contrarian setup. We're selling the $10 put expiring in June 2026 for $0.30, essentially g

Selling puts on a trucking company trading at 50x earnings? In this market, that's practically value investing. SAIA sits 16% above its 50-day moving average and 36% above its 200-day, sporting a beta

Revvity's recent FDA clearance for its testosterone assay isn't just another regulatory checkbox—it's a glimpse into how this diagnostics player keeps expanding its testing portfolio. With the stock s

UiPath trades like yesterday's AI darling while building tomorrow's automation backbone. At $11.16, PATH sits 14% below its 200-day moving average despite sporting a healthy 17.5% profit margin and re

CRISPR Therapeutics trades like a biotech startup despite being a clinical-stage gene editing pioneer with actual approved therapies. At $51.59, CRSP sits near its 50-day moving average but well below

IBM is offering a rare gift: 49.5% implied volatility on a stock that barely moves. At $253.84, Big Blue sits comfortably above our $235 strike with 31 days to expiration, collecting $6.35 in premium

While everyone's chasing AI darlings at nosebleed valuations, GDS Holdings sits quietly in the corner — a Chinese data center operator trading at $40.41 with analysts pointing to $57. We're selling th

Corporate payments are having a moment, and Corpay is cashing in. The $11.8 billion fintech sits at the intersection of two massive trends: the digitization of B2B payments and the cross-border money

Investment banking boutiques have been swimming upstream for two years, but Lazard's latest moves suggest the current might be shifting. The $43 put on LAZ delivers 3.0% in 34 days — that's 32% annual

When homebuilders trade at 10.9x earnings while the S&P 500 sits north of 25x, someone's not paying attention. Century Communities (CCS) is down 15% from its 50-day moving average and 22% off its 200-